Core Insights - AtriCure reported $134.27 million in revenue for Q3 2025, a 15.8% year-over-year increase, with an EPS of -$0.01 compared to -$0.17 a year ago, indicating significant improvement in profitability [1] - The revenue exceeded the Zacks Consensus Estimate by 2.09%, while the EPS surprise was 90.91% above the consensus estimate [1] Revenue Performance - U.S. revenue from pain management reached $20.84 million, surpassing the average estimate of $20.59 million, reflecting a 27.7% year-over-year increase [4] - International revenue from pain management was $2.08 million, below the average estimate of $2.77 million, but still showing a 30.8% year-over-year increase [4] - U.S. revenue from total ablation was $43.02 million, significantly below the average estimate of $63.41 million, marking a 25.9% year-over-year decline [4] - International revenue from total ablation was $12.71 million, slightly below the average estimate of $14.54 million, but showing a 7% year-over-year increase [4] - Total U.S. revenue was $109.31 million, exceeding the average estimate of $106.47 million, with a 14.5% year-over-year increase [4] - International revenue from appendage management was $10.17 million, below the average estimate of $10.58 million, reflecting an 18.5% year-over-year increase [4] - U.S. revenue from open ablation was $35.59 million, slightly above the average estimate of $34.88 million, with a 16.3% year-over-year increase [4] - International revenue from open ablation was $10.85 million, exceeding the average estimate of $9.73 million, marking a 26.1% year-over-year increase [4] - U.S. revenue from minimally invasive ablation was $7.43 million, below the average estimate of $7.94 million, showing a 33.2% year-over-year decline [4] - International revenue from minimally invasive ablation was $1.86 million, below the average estimate of $2.04 million, but reflecting a 10.8% year-over-year increase [4] - U.S. revenue from appendage management was $45.45 million, exceeding the average estimate of $43.06 million, with a 21.5% year-over-year increase [4] - Total international revenue was $24.96 million, slightly below the average estimate of $25.12 million, but showing a 22% year-over-year increase [4] Stock Performance - AtriCure's shares have returned 3.4% over the past month, compared to a 3.8% change in the Zacks S&P 500 composite, indicating a performance in line with the broader market [3]

Core Insights - AtriCure reported revenue of $136.14 million for the quarter ended June 2025, reflecting a year-over-year increase of 17.1% and surpassing the Zacks Consensus Estimate of $130.15 million by 4.61% [1] - The company achieved an EPS of -$0.02, a significant improvement from -$0.17 in the same quarter last year, resulting in an EPS surprise of 86.67% against the consensus estimate of -$0.15 [1] Revenue Performance - U.S. Revenue in Pain Management reached $21.17 million, exceeding the average estimate of $18.36 million, marking a year-over-year increase of 41.1% [4] - International Revenue in Pain Management was $2.03 million, slightly below the average estimate of $2.24 million, but still showing a year-over-year growth of 63.8% [4] - U.S. Revenue for Total Ablation was $44.31 million, falling short of the average estimate of $62.64 million, representing a decline of 23.1% year-over-year [4] - International Revenue for Total Ablation was $12.72 million, compared to the average estimate of $14.37 million, with a year-over-year increase of 4.5% [4] - Total U.S. Revenue amounted to $110.58 million, surpassing the average estimate of $105.65 million, reflecting a year-over-year growth of 15.8% [4] - International Revenue for Appendage Management was $10.8 million, exceeding the average estimate of $10.33 million, with a year-over-year increase of 26.3% [4] - U.S. Revenue for Open Ablation was $36.47 million, slightly above the average estimate of $35.47 million, showing an 18.6% increase year-over-year [4] - International Revenue for Open Ablation reached $10.35 million, exceeding the average estimate of $10.15 million, with a year-over-year growth of 12.9% [4] - U.S. Revenue for Minimally Invasive Ablation was $7.84 million, below the average estimate of $8.81 million, reflecting a decline of 33.7% year-over-year [4] - International Revenue for Minimally Invasive Ablation was $2.37 million, surpassing the average estimate of $1.98 million, with a year-over-year increase of 34.5% [4] - U.S. Revenue for Appendage Management was $45.11 million, exceeding the average estimate of $43.01 million, representing an 18.9% year-over-year increase [4] - Total International Revenue was $25.56 million, surpassing the average estimate of $24.69 million, with a year-over-year growth of 23.3% [4] Stock Performance - AtriCure's shares have returned +1.4% over the past month, compared to the Zacks S&P 500 composite's +3.6% change, indicating a performance in line with the broader market [3]